2023
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
Shoukat A, Abdollahi E, Galvani A, Halperin S, Langley J, Moghadas S. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. The Lancet Regional Health - Americas 2023, 28: 100629. PMID: 38026446, PMCID: PMC10663690, DOI: 10.1016/j.lana.2023.100629.Peer-Reviewed Original ResearchEntire birth cohortPregnant womenBirth cohortCost-effectiveness analysisRSV seasonHigh riskBudget impactRespiratory syncytial virus diseaseSocietal perspectiveAnnual budget impactFirst RSV seasonHealth benefitsRespiratory syncytial virusImmunisation of infantsYears of ageLow budget impactMonths of ageNet monetary benefitMaternal vaccinesRSV infectionPassive immunisationGestational ageImmunisation strategiesSyncytial virusVaccine strategies
2022
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Mao T, Israelow B, Peña-Hernández MA, Suberi A, Zhou L, Luyten S, Reschke M, Dong H, Homer RJ, Saltzman WM, Iwasaki A. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 2022, 378: eabo2523. PMID: 36302057, PMCID: PMC9798903, DOI: 10.1126/science.abo2523.Peer-Reviewed Original ResearchConceptsRespiratory mucosaSystemic immunityLethal SARS-CoV-2 infectionAcute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemicSARS-CoV-2 infectionProtective mucosal immunityCross-reactive immunityT cell responsesCoronavirus 2 pandemicPrimary vaccinationParenteral vaccinesMucosal immunityVaccine strategiesRespiratory tractImmunoglobulin AMemory BImmune memoryPartial immunityCell responsesPoor immunityImmunitySpike proteinMucosaVaccineOperation Nasal Vaccine—Lightning speed to counter COVID-19
Topol EJ, Iwasaki A. Operation Nasal Vaccine—Lightning speed to counter COVID-19. Science Immunology 2022, 7: eadd9947. PMID: 35862488, DOI: 10.1126/sciimmunol.add9947.Peer-Reviewed Original Research
2021
Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA
Oh JE, Song E, Moriyama M, Wong P, Zhang S, Jiang R, Strohmeier S, Kleinstein SH, Krammer F, Iwasaki A. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. Science Immunology 2021, 6: eabj5129. PMID: 34890255, PMCID: PMC8762609, DOI: 10.1126/sciimmunol.abj5129.Peer-Reviewed Original ResearchConceptsVirus infectionIgA secretionB cellsMucosal surfacesIgA-secreting B cellsIgA-expressing cellsRole of IgARespiratory virus infectionsIgA-secreting cellsLower respiratory tractInfluenza virus infectionEffective immune protectionHeterologous virus infectionMemory B cellsSecretory immunoglobulin AProtein-based vaccinesB cell populationsPredominant Ig isotypeSite of entryIntranasal primingBronchoalveolar spaceProtective immunityVaccine strategiesRespiratory mucosaImmune protectionPrevention of host-to-host transmission by SARS-CoV-2 vaccines
Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, Iwasaki A. Prevention of host-to-host transmission by SARS-CoV-2 vaccines. The Lancet Infectious Diseases 2021, 22: e52-e58. PMID: 34534512, PMCID: PMC8439617, DOI: 10.1016/s1473-3099(21)00472-2.Peer-Reviewed Original ResearchConceptsSARS-CoV-2SARS-CoV-2 vaccinesSymptomatic COVID-19Population-level dataVaccine's abilityIntramuscular vaccineImmunological mechanismsVaccine strategiesVaccine capacityPrimary infectionNatural courseClinical trialsObservational studyRespiratory epitheliumReal-world settingViral titresViral replicationVaccineVaccine distributionInfectionCOVID-19Host transmissionTrialsPopulation-level effectsMucosaSARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain
Bayarri-Olmos R, Idorn M, Rosbjerg A, Pérez-Alós L, Hansen C, Johnsen L, Helgstrand C, Zosel F, Bjelke J, Öberg F, Søgaard M, Paludan S, Bak-Thomsen T, Jardine J, Skjoedt M, Garred P. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. The Journal Of Immunology 2021, 207: 878-887. PMID: 34301847, DOI: 10.4049/jimmunol.2100272.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin-Converting Enzyme 2AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCoronavirus Nucleocapsid ProteinsCOVID-19COVID-19 SerotherapyCOVID-19 VaccinesEnzyme-Linked Immunosorbent AssayHumansImmunizationImmunization, PassiveImmunoglobulin AImmunoglobulin GImmunoglobulin MMiceNeutralization TestsProtein DomainsReceptors, VirusSARS-CoV-2Spike Glycoprotein, CoronavirusConceptsPlaque reduction neutralization testReceptor-binding domainReduction neutralization testNeutralization testFull-length spike proteinSARS-CoV-2 transmissionSARS-CoV-2 receptor-binding domainViral neutralization testSARS-CoV-2Levels of AbsIgG titersVaccine strategiesAntibody responsePreclinical modelsConvalescent seraImmune responseMouse modelNeutralization potencyVirus neutralizationFull spikesImmunization strategiesMurine mAbsImmunization resultsSpike proteinELISATandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
Branagan AR, Duffy E, Gan G, Li F, Foster C, Verma R, Zhang L, Parker TL, Seropian S, Cooper DL, Brandt D, Kortmansky J, Witt D, Ferencz TM, Dhodapkar KM, Dhodapkar MV. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. Blood Advances 2021, 5: 1535-1539. PMID: 33683337, PMCID: PMC7948269, DOI: 10.1182/bloodadvances.2020003880.Peer-Reviewed Original ResearchConceptsHigh-dose influenza vaccinationPlasma cell dyscrasiaInfluenza vaccinationProtective immunityCell dyscrasiaPCD patientsPlacebo-controlled clinical trialHigh-dose vaccinationHigh-dose vaccineInfluenza-specific immunityBurden of influenzaSaline placebo injectionsAge-based vaccinationHigher seroprotectionSerologic immunityPlacebo injectionsVaccine strategiesTiter responseClinical trialsFlu seasonPatientsVaccinationImmunityNovel coronavirusSeroprotectionAgBR1 and NeSt1 antisera protect mice from Aedes aegypti-borne Zika infection
Marin-Lopez A, Wang Y, Jiang J, Ledizet M, Fikrig E. AgBR1 and NeSt1 antisera protect mice from Aedes aegypti-borne Zika infection. Vaccine 2021, 39: 1675-1679. PMID: 33622591, PMCID: PMC7990057, DOI: 10.1016/j.vaccine.2021.01.072.Peer-Reviewed Original ResearchConceptsMosquito saliva proteinsPassive immunizationZIKV infectionEarly host responseDiverse clinical symptomsViral burdenSaliva proteinsClinical symptomsVaccine strategiesZika infectionHost responseModel antigenInfectionPartial protectionMiceImmunizationZIKVAntiserumIndividual antiseraAgBR1ViremiaSymptomsAntigenBloodAntibodiesThe SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization
Bayarri-Olmos R, Rosbjerg A, Johnsen L, Helgstrand C, Bak-Thomsen T, Garred P, Skjoedt M. The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. Journal Of Biological Chemistry 2021, 296: 100536. PMID: 33716040, PMCID: PMC7948531, DOI: 10.1016/j.jbc.2021.100536.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SubstitutionAngiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntibodies, ViralConvalescenceCOVID-19DenmarkGene ExpressionHEK293 CellsHost-Pathogen InteractionsHumansImmune SeraImmunity, InnateMinkModels, MolecularMutationPandemicsProtein BindingProtein Structure, SecondaryRecombinant ProteinsSARS-CoV-2Spike Glycoprotein, CoronavirusVirus InternalizationConceptsReceptor-binding domainSevere acute respiratory syndrome coronavirus 2Angiotensin-converting enzyme 2 receptorAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Human angiotensin-converting enzyme 2 (ACE2) receptorPotential immune evasionSyndrome coronavirus 2Enzyme 2 (ACE2) receptorSpike gene mutationsBiolayer interferometry analysisVaccine strategiesCoronavirus 2Humoral immunityAntibody responseViral controlImmune responseMouse modelImmune evasionAntibody neutralizationReceptor adaptationOriginal WuhanSpike proteinGene mutationsGenetic variants
2020
Cutting Edge: The Use of Topical Aminoglycosides as an Effective Pull in "Prime and Pull" Vaccine Strategy.
Gopinath S, Lu P, Iwasaki A. Cutting Edge: The Use of Topical Aminoglycosides as an Effective Pull in "Prime and Pull" Vaccine Strategy. The Journal Of Immunology 2020, 204: 1703-1707. PMID: 32122994, PMCID: PMC11694766, DOI: 10.4049/jimmunol.1900462.Peer-Reviewed Original ResearchConceptsTissue-resident memory T cellsGenital herpes infectionMemory T cellsT cellsHerpes infectionVirus-specific effector T cellsVaginal applicationTopical vaginal applicationCD8 T cellsEffector T cellsProtective immune responseSingle topical applicationTopical aminoglycosidesGenital mucosaChemokine expressionVaccine strategiesImmune responseVaginal mucosaTopical applicationBarrier tissuesMiceRobust activationAminoglycoside antibioticsMucosaInfection
2018
Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study
White SE, Harvey SA, Meza G, Llanos A, Guzman M, Gamboa D, Vinetz JM. Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study. Malaria Journal 2018, 17: 179. PMID: 29703192, PMCID: PMC5921293, DOI: 10.1186/s12936-018-2328-z.Peer-Reviewed Original ResearchConceptsTransmission-blocking malaria vaccineTransmission-blocking vaccinesMalaria vaccineMalaria transmission-blocking vaccineMalaria hypoendemic regionMalaria vaccine strategyProspective cohort studyMalaria-endemic communitiesMalaria-endemic regionsPre-validated questionnaireCohort studyVaccine strategiesMalaria infectionMethodsThe studyVaccineMalaria controlMalaria researchMultiple injectionsOne-thirdIndustrialized worldInjectionAcceptabilityCohortInfectionStudy
2017
AGE-RELATED CHANGES IN INNATE IMMUNE CELL FUNCTION
Montgomery R. AGE-RELATED CHANGES IN INNATE IMMUNE CELL FUNCTION. Innovation In Aging 2017, 1: 1254-1254. PMCID: PMC6183893, DOI: 10.1093/geroni/igx004.4559.Peer-Reviewed Original ResearchInnate immune cellsImmune cellsInnate immune cell functionLevels of TLR5Natural killer cellsToll-like receptorsImmune cell functionAge-Associated DecreasePotential therapeutic opportunitiesAge-related changesVaccine responsesKiller cellsVaccine strategiesOlder donorsImmune functionOlder subjectsTherapeutic opportunitiesInfectious diseasesProgressive declinePrimary humanCell functionMass cytometrySurface expressionReduced levelsReduced production
2015
Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders
Branagan A, Duffy E, Boddupall C, Albrecht R, Zhang L, Verma R, Cooper D, Seropian S, Parker T, Yao X, Ferencz T, Dhodapkar M. Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. Blood 2015, 126: 3058. DOI: 10.1182/blood.v126.23.3058.3058.Peer-Reviewed Original ResearchHigh-dose influenza vaccineHigh-dose vaccinePlasma cell disordersNovel vaccination strategiesProtective HAI titersCell-mediated immunityMultiple myeloma patientsNovel vaccine strategiesInfluenza vaccineVaccination strategiesSignificant unmet needInfluenza vaccinationHAI titersPCD patientsCell disordersFlu seasonSecondary endpointsSeroprotection ratesDose vaccineMyeloma patientsVaccine strategiesFlu infectionUnmet needInfection rateGrade 2 adverse eventsCandida albicans Morphology and Dendritic Cell Subsets Determine T Helper Cell Differentiation
Kashem SW, Igyártó B, Gerami-Nejad M, Kumamoto Y, Mohammed J, Jarrett E, Drummond RA, Zurawski SM, Zurawski G, Berman J, Iwasaki A, Brown GD, Kaplan DH. Candida albicans Morphology and Dendritic Cell Subsets Determine T Helper Cell Differentiation. Immunity 2015, 42: 356-366. PMID: 25680275, PMCID: PMC4343045, DOI: 10.1016/j.immuni.2015.01.008.Peer-Reviewed Original ResearchConceptsT helper cell responsesHelper cell responsesCell responsesInterleukin-6Systemic infectionDectin-1 ligationTh1 cell responsesTh cell responsesT helper 17 (Th17) cell differentiationT helper cell differentiationTissue-specific protectionSkin infection modelMurine skin infection modelC. albicansHelper cell differentiationMucocutaneous immunityCutaneous infectionsVaccine strategiesLangerhans cellsSystemic immunityT cellsCell differentiationInfection modelInfectionImmunity
2014
A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells
Iijima N, Iwasaki A. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science 2014, 346: 93-98. PMID: 25170048, PMCID: PMC4254703, DOI: 10.1126/science.1257530.Peer-Reviewed Original ResearchConceptsMemory lymphocyte clustersMemory T cellsT cellsCD8 tissue-resident memory T cellsTissue-resident memory CD4 T cellsHerpes simplex virus 2 infectionTissue-resident memory T cellsSimplex virus 2 infectionMemory CD4 T cellsEfficient local controlPool of CD4Role of CD4CD4 T cellsVirus 2 infectionVaginal CD4Parabiotic miceGenital mucosaVaccine strategiesChemokine networkLymphocyte clustersHSV-2Viral infectionCD4Local controlInfection
2013
Specific immunotherapy modifies allergen-specific CD4+ T-cell responses in an epitope-dependent manner
Wambre E, DeLong JH, James EA, Torres-Chinn N, Pfützner W, Möbs C, Durham SR, Till SJ, Robinson D, Kwok WW. Specific immunotherapy modifies allergen-specific CD4+ T-cell responses in an epitope-dependent manner. Journal Of Allergy And Clinical Immunology 2013, 133: 872-879.e7. PMID: 24373351, PMCID: PMC3961577, DOI: 10.1016/j.jaci.2013.10.054.Peer-Reviewed Original ResearchConceptsT cell responsesGrass pollen allergyAllergen-specific immunotherapyPollen allergyAllergen-specific T-cell responsesAllergen-specific Th2 cellsAllergen-specific CD4Epitope-dependent mannerEpitope hierarchyTr1 responsesTr1 cellsNonatopic subjectsAllergic inflammationPeripheral toleranceAllergic subjectsVaccine strategiesTh2 cellsAntigen stimulationDistinct functional profilesT cellsEpitope levelAllergyEpitope changesImmunotherapyCell deletionEnhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors
Furlan SN, Mandraju R, Brewer T, Roybal K, Troutman TD, Hu W, Palm NW, Unni A, Pasare C. Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors. MAbs 2013, 6: 108-118. PMID: 24284965, PMCID: PMC3929435, DOI: 10.4161/mabs.27052.Peer-Reviewed Original ResearchConceptsT cell responsesFc receptorsTumor cellsT cellsAnti-tumor T cell responsesCell responsesEffective anti-tumor responseAnti-tumor CD8DC vaccine strategiesDendritic cell functionTumor-derived antigensAnti-tumor responseTumor-specific antigensFc regionTherapeutic tumor vaccinesInnate immune responseIgG1 Fc regionSuch tumor cellsSurface of tumorVariety of receptorsProfessional antigenTumor vaccinesVaccine strategiesAntigen uptakePrimary tumorPanel 6: Vaccines
Pelton SI, Pettigrew MM, Barenkamp SJ, Godfroid F, Grijalva CG, Leach A, Patel J, Murphy TF, Selak S, Bakaletz LO. Panel 6: Vaccines. Otolaryngology 2013, 148: e90-e101. PMID: 23536534, PMCID: PMC4029613, DOI: 10.1177/0194599812466535.Peer-Reviewed Original ResearchConceptsAcute otitis mediaPneumococcal conjugate vaccineOtitis mediaDevelopment of correlatesCandidate antigensAnimal modelsClinical efficacy trialsEffectiveness of vaccinesBurden of diseaseNontypeable Haemophilus influenzaeHuman clinical trialsOtitis pathogensConjugate vaccineVaccine strategiesPneumococcal serotypesClinical trialsMoraxella catarrhalisAdditional serotypesNew adjuvantsEfficacy trialsObservational studyFrequent recurrenceChild healthVaccine antigensMore antigens
2012
A vaccine strategy that protects against genital herpes by establishing local memory T cells
Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012, 491: 463-467. PMID: 23075848, PMCID: PMC3499630, DOI: 10.1038/nature11522.Peer-Reviewed Original ResearchConceptsMemory T cellsVaccine strategiesT cellsTissue-resident memory T cellsGenital herpesCellsHerpesImmunization
2008
Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.
Wilson SR, Wilson JH, Buonocore L, Palin A, Rose JK, Reuter JD. Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity. Journal Of The American Association For Laboratory Animal Science 2008, 58: 129-39. PMID: 18524170, PMCID: PMC2703170.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAnimalsAntibody FormationCD8-Positive T-LymphocytesDNA, RecombinantDNA, ViralFemaleHerpesviridae InfectionsImmunity, CellularImmunizationInterferon-gammaMaleMiceMice, Inbred C57BLMuromegalovirusNeutralization TestsSpecific Pathogen-Free OrganismsSpleenVesiculovirusViral Envelope ProteinsViral VaccinesConceptsRecombinant vesicular stomatitis virusMurine cytomegalovirusIntranasal immunizationCellular immunityVesicular stomatitis virusSingle intranasal vaccinationStomatitis virusValuable animal modelIntranasal vaccinationMucosal vaccinationImmunized miceVaccine strategiesIFNgamma responsesVaccine prophylaxisCell surface expressionLeading causeImmune responseMouse modelVaccine vectorLive virusAnimal modelsViral infectionStrong cytoplasmicMajor envelope proteinSurface expression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply